Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gallbladder cancer (GBC) is a lethal biliary tract malignancy with limited treatment options.
• Identifying novel therapeutic targets is crucial for improving patient outcomes in GBC.

Purpose of the Study:

• To identify actionable molecular vulnerabilities in GBC.
• To evaluate the therapeutic potential of targeting the ErbB and epigenetic pathways in GBC.
• To investigate the prognostic significance of mTOR pathway activation in GBC.

Main Methods:

• Whole-exome sequencing of human GBC samples.
• Screening of small-molecule libraries targeting ErbB and epigenetic pathways.
• In vitro proliferation assays and in vivo tumor growth/metastasis models in mice.
• Immunohistochemical analysis of phosphorylated mTOR (p-mTOR) and S6K1 (p-S6K1) in clinical GBC samples.

Main Results:

• The mTOR inhibitor INK-128 and HDAC inhibitor JNJ-26481585 significantly inhibited GBC cell proliferation.
• Both compounds suppressed tumor growth and metastasis in preclinical mouse models.
• INK-128 and JNJ-26481585 demonstrated synergistic effects with gemcitabine.
• Activation of the mTOR pathway (p-mTOR and p-S6K1) correlated with poor prognosis and was an independent predictor of overall survival in GBC patients.

Conclusions:

• mTOR inhibitors and HDAC inhibitors represent promising therapeutic strategies for GBC.
• Targeting the mTOR pathway offers potential for novel GBC treatments.
• p-mTOR and p-S6K1 serve as valuable biomarkers for predicting GBC patient prognosis.